Why Hoya MiYOSMART keeps turning heads in children’s myopia control

Hoya MiYOSMART promises something very concrete for parents and eye-care professionals alike - slowing down myopia progression in children with a lens that looks and feels like a normal pair of glasses. What does the daily reality with this discreet technology look like?

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 14:07. Details in the imprint.

With Hoya MiYOSMART, parents see an ordinary pair of children’s glasses on the table, while inside the lenses a quiet pattern of treatment zones works all day to slow down myopia. The frames feel light, the routine stays normal, the promise is long-term eye health.

How MiYOSMART actually works

The core of Hoya MiYOSMART is a specially designed spectacle lens with what the company calls a Defocus Incorporated Multiple Segments (DIMS) design. Tiny treatment zones are embedded across the lens surface, barely visible in daily use, but crucial for altering peripheral focus on the retina.

According to Hoya, this controlled myopic defocus is intended to send a continuous "stop signal" to the growing eye, slowing axial elongation without needing eye drops or contact lenses. Children simply wear their glasses as usual for school, sports, and screen time, which makes adherence much easier for families.

What everyday wear feels like

On the nose, MiYOSMART lenses feel very similar to standard single-vision lenses paired with a light children’s frame. There is no mechanical moving part, no buzzing device, no app that needs constant connection. Kids put them on in the morning and largely forget about them.

Parents, meanwhile, tend to notice the subtle grid-like reflection when the lens catches the light at certain angles. Many opticians report that after a short explanation, children adapt quickly and do not complain about distorted vision, as the central zone is optimized for clear distance viewing.

The evidence that backs the promise

The confidence around MiYOSMART stands on clinical data rather than marketing slogans. A key two-year randomized controlled trial in Hong Kong found that children wearing the DIMS lens showed about 60 percent less myopia progression and axial elongation compared with those in standard single-vision lenses.

More recently, Hoya has highlighted long-term follow-up data showing that the slowing effect appears to persist with extended wear and that stopping MiYOSMART after several years does not trigger a dramatic rebound in progression, a point that matters for cautious parents and clinicians.

Which children it aims to help

MiYOSMART targets school-age children with progressive myopia, typically from around age 6 to the mid-teens, where the eye still grows rapidly. It is particularly interesting in regions such as East Asia, where myopia prevalence in teenagers has reached extremely high levels.

However, European optometrists and ophthalmologists are also starting to integrate MiYOSMART into treatment pathways, often alongside lifestyle advice such as more outdoor time and structured near-work breaks. The lens is usually offered after a detailed myopia-management consultation rather than as an off-the-shelf product.

Availability and how to get it

Unlike a mass-market online product, MiYOSMART is distributed through selected eye-care professionals who have completed Hoya’s training modules. Parents typically undergo a full refraction and axial length measurement for their child before an optician orders the customized lenses from Hoya’s labs.

The product launched first in parts of Asia in 2018 and has since been rolled out to Europe, including Germany, and other regions. Pricing sits clearly above standard single-vision pediatric lenses, reflecting the clinical positioning, but remains far below the yearly cost of many specialty contact lens or pharmacological regimens.

Strengths, trade-offs, and open questions

One clear strength of MiYOSMART is its simplicity. There is no need for children to touch their eyes as with contact lenses, and the risk of infection from poor hygiene is lower. For many families, that alone is a decisive argument when weighing options.

The trade-offs are more subtle. Because the lens structure imposes controlled peripheral defocus, some children report minor adaptation effects in the first days, such as noticing halos in peripheral vision. Eye-care professionals usually address this through careful frame fitting and counseling so the central zone stays correctly aligned.

Where MiYOSMART sits in the myopia toolbox

MiYOSMART does not exist in a vacuum. It competes and often combines with other evidence-based myopia-management tools like low-dose atropine eye drops, orthokeratology (overnight reshaping lenses), and newer soft multifocal contact lenses. Many specialists now talk about a personalized mix rather than a single magic bullet.

In that landscape, Hoya’s lens is appealing because it slots into a familiar habit: wearing glasses. Clinics that already have a strong pediatric base frequently add MiYOSMART as a mid-priced, non-invasive option for parents who are hesitant about drops or contacts but want more than "wait and see".

What this means for Hoya as a business

For Hoya Corp, MiYOSMART is strategically important because it pushes the company beyond commodity lenses into a higher-margin, clinically differentiated segment. The global rise of childhood myopia, especially in Asia and increasingly in Europe, gives this category structural growth potential.

Shares of Hoya Corp (JP3300200007) trade in Tokyo, where the company is a widely followed constituent of the local blue-chip indices.

Key facts on Hoya MiYOSMART

• Product: Hoya MiYOSMART
• Manufacturer: Hoya Corp
• Category: Software/Service/Subscription - myopia-control lens program via trained professionals
• Launch: Initial launch in Asia around 2018, later roll-out to Europe
• RRP / Price: Positioned above standard single-vision children’s lenses, pricing set individually by opticians
• Availability: Via selected opticians and eye clinics in Asia and Europe, including Germany
• Target group: School-age children with progressing myopia and their parents
• Highlight / USP: Clinically validated spectacle lens design that slows myopia progression while looking and feeling like normal glasses

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.